18 citations
,
January 2021 in “Theranostics” This study found that actively targeted AN2728-loaded nanocarriers reduced inflammation and improved skin condition in a mouse model of psoriasiform inflammation compared to free drug and non-targeted nanoparticles.
278 citations
,
March 2013 in “Gut” In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.
September 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” This study, involving a retrospective analysis of 24 patients in France, found that paradoxical psoriasiform alopecic reactions on the scalp associated with TNFα-targeted therapies for inflammatory bowel disease are rare yet non-scarring, with all patients achieving complete hair regrowth within two months after treatment adjustments.
April 2023 in “Journal of Investigative Dermatology” This study found that NIMP-R14-conjugated nanoparticles, loaded with roflumilast, effectively targeted neutrophils to reduce inflammation and improve symptoms in a mouse model of psoriasiform dermatitis, suggesting potential for targeted therapy in autoimmune skin diseases.
April 2017 in “Journal of Investigative Dermatology” This study found that fisetin, a dietary flavonoid, significantly improved psoriasiform skin lesions in mice by promoting cell differentiation, inhibiting proliferation, and modulating inflammatory responses.